Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo Plus FLOT for Resectable Gastric or GEJ Adenocarcinoma By Ogkologos - June 10, 2025 728 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Datopotamab Deruxtecan Improves Survival Over Chemotherapy in Patients with Previously Untreated,... April 28, 2026 ESMO Welcomes New Cancer Focused UN Political Declaration on Non-Communicable Diseases October 6, 2025 “Chameleon-Like” Breast Cancer Cells Disguised as Neurons Can Lead to Brain... June 8, 2021 Addressing Common Sexual Health Concerns During Cancer Survivorship: An Expert Perspective January 17, 2023 Load more HOT NEWS As More People with Cancer Use Medical Cannabis, Oncologists Face Questions... Six Years of Adjuvant Imatinib Improves DFS Over Three Years Treatment... More Than 25 Additional Years Needed to Slow an Increasing Incidence... Higher Risk of Heart Failure Seen in Some Cancers
